Dermatological toxity of alpelisib: clinical experience and review of current guidelines
- Authors: Gordeeva O.O1, Ganshina I.P1, Garifullina V.I2
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- City Clinical Hospital № 40
- Issue: Vol 28, No 7 (2021)
- Pages: 28-32
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313175
- DOI: https://doi.org/10.18565/pharmateca.2021.7.28-32
- ID: 313175
Cite item
Open Access
Access granted
Abstract
Alpelisib is a new drug registered in Russia in 2020 for patients with luminal HER2- metastatic breast cancer with a confirmed mutation in the PIK3CA gene, who have developed resistance against the background of previous endocrine therapy. The results of the SOLAR-1 and BYLieve trials demonstrated not only the effectiveness of the drug, but also new types of toxicity inherent in this therapy. To date, recommendations for the prevention and treatment of the most common adverse events, which make it possible to use the drug as safely as possible, have been developed. This article presents our own clinical experience with the use of Alpelisib with an emphasis on dermatological toxicity, as well as an overview of current recommendations devoted to this problem.
Full Text
About the authors
O. O Gordeeva
N.N. Blokhin National Medical Research Center of Oncology
Email: gordeeva.md@yandex.ru
Moscow, Russia
I. P Ganshina
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
V. I Garifullina
City Clinical Hospital № 40Moscow, Russia
References
- Anderson W.F, et ai. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76:27-36. doi: 10.1023/a:1020299707510.
- Cardoso F, Paiuch-Shimon S., Senkus E., et ai. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncoi. 2020;31(12):1623-49. Doi: 10.1016/j. annonc.2020.09.010.
- Beaver J.A., et ai., The BOLERO-2 trial: The addition of everoiimus to exemestane in the treatment of postmenopausai hormone receptorpositive advanced breast cancer. Future Oncoi. 2012;8:651-57. doi: 10.2217/fon.12.49.
- Andre F, Cirueios E., Rubovszky G., et ai. Aipeiisib for PlK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engi J Med. 2019;380:1929-40. Doi: 10.1056/ NEJMoa1813904.
- Andre F, Cirueios E.M., Juric D., et ai. Overaii survivai resuits from SOLAR-1, a phase III study of aipeiisib+fuivestrant for hormone receptorpositive, human epidermai growth factor receptor 2-negative advanced breast cancer. ESMO Virtuai Congress 2020. Abstract LBA18. Presented September 19, 2020.
- Rugo H.S., Lerebours F, Cirueios E., et ai. Aipeiisib pius fuivestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, muiticentre, open-iabei, non-comparative study. Lancet. Oncoi. 2021;22(4):489-98. doi: 10.1016/S1470-2045(21)00034-6.
- Bossi P, Antonuzzo A., Cherny N.I., et ai. ESMO Guideiines Committee. Diarrhoea in aduit cancer patients: ESMO Ciinicai Practice Guideiines. Ann Oncoi. 2018;29(Suppi. 4):S126-42. doi: 10.1093/annonc/mdy145.
- Мазурина Н.В., Артамонова Е.В., Белоярцева М.Ф. и др. Консенсус по профилактике и коррекции гипергликемии у пациентов, получающих терапию препаратом алпелисиб. Современная онкология. 2020;22(4):56-9.
- Wang D.G., Barrios D.M., Biinder VS., et ai. Dermatoiogic adverse events reiated to the PI3Ka inhibitor aipeiisib (BYL719) in patients with breast cancer. Breast Cancer Res Treat. 2020;183(1):227-37. doi: 10.1007/s10549- 020- 05726-y.
- Инструкция по медицинскому применению лекарственного препарата Пикрэй (NPI v 0.2 fuii approved on 19-June-2020Based on CDS- 21- Nov-2018 version 1.0).
- Nunnery S.E., Mayer I.A. Management of toxicity to isoform a-specific PI3K inhibitors. Ann Oncoi. 2019;30(Suppi. 10):S21-6. Doi: 10.1093/ annonc/mdz440.
- Rugo H.S., Andre F., Yamashita T., et ai. 324P -Aipeiisib (ALP)+fuivestrant (FUL) for patients with hormone receptor-positive (HR+), HER2 advanced breast cancer (ABC): Management and time course of key adverse events of speciai interest (AESIs) in SOLAR-1. Ann Oncoi. 2019;30(Suppi. 5):S112-13.
Supplementary files
